Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adagio Medical Holdings (ADGM) Change in Cash (2023 - 2026)

Adagio Medical Holdings (ADGM) reported Change in Cash of -$4.2 million for Q1 2026, up 44.96% year-over-year from -$2.9 million in Q1 2025, and down 133.75% on a QoQ basis from $12.4 million in Q4 2025.

Adagio Medical Holdings (ADGM) has 4 years of Change in Cash data on file, last reported at -$4.2 million in Q1 2026.

  • Quarterly Change in Cash rose 44.96% year-over-year to -$4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.3 million (down 77.83% YoY) and the FY2025 annual result came in at -$3.5 million, up 76.11% from the prior year.
  • Change in Cash fell to -$4.2 million in Q1 2026 per ADGM's latest filing, from $12.4 million in the prior quarter.
  • Across five years, Change in Cash topped out at $12.4 million in Q4 2025 and bottomed at -$7.6 million in Q1 2025.
  • The 4-year median for Change in Cash is -$598000.0 (2023), against an average of $586571.4.
  • The widest annual swing landed in 2025, when Change in Cash sank 382.33%; it then soared 44.96% in 2026.
  • Tracing ADGM's Change in Cash over 4 years: stood at -$598000.0 in 2023, then sank by 1052.84% to -$6.9 million in 2024, then surged by 280.33% to $12.4 million in 2025, then sank by 133.75% to -$4.2 million in 2026.
  • Per Business Quant, the three latest ADGM Change in Cash figures stand at -$4.2 million (Q1 2026), $12.4 million (Q4 2025), and -$7.6 million (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Cash (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -1.72 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -1.13 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -136.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -504.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -492.00 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 199.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.23 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 15.90 Mn
10 Adagio Medical Holdings 16.86 Mn 3.95 Mn - -4.20 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -4.20 Mn
Dec 31, 2025 12.43 Mn
Mar 31, 2025 -7.62 Mn
Sep 30, 2024 -6.89 Mn
Jun 30, 2024 8.29 Mn
Mar 31, 2024 2.70 Mn
Dec 31, 2023 -598,000.00